Cost-effectiveness of Oncotype DX® to target chemotherapy use in lymph-node-negative, oestrogen-receptor-positive, early-stage breast cancer in Ireland.
Pharmacoeconomic Evaluation
| Commenced | Completed | Outcome |
| 24/05/2011 | 22/07/2011 | Reimbursement not recommended at the submitted price |
3rd October 2011
Following a price revision the NCPE now consider Oncotype DX a cost-effective therapy to target chemotherapy use in lymph-node-negative, oestrogen-receptor-positve, early stage breast cancer in Ireland.
July 2013
The HSE has approved reimbursement following confidential price negotiations.
